Search
2025
2024
2023
-
Jun 06, 2025
YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)Read More
-
May 28, 2025
YolTech Therapeutics Appoints Dr. Alexandre Moreau to Lead Global Business DevelopmentRead More
-
Apr 28, 2025
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial HypercholesterolemiaRead More
-
Apr 10, 2025
YolTech Receives U.S. FDA ODD for YOLT-202 in Treating AATDRead More
-
Mar 26, 2025
YolTech Therapeutics Announces Favorable Interim Results from Ongoing IIT that Single-Dose Administration of YOLT-101, an In Vivo Gene Editing Therapy, Effectively Reduces LDL-C in Familial HypercholesterolemiaRead More
